Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00433407 · ClinicalTrials.gov registry record · NA
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
A NA study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00433407 is a NA study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT00433407, a NA study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at blood samples from patients receiving trastuzumab and/or chemotherapy for HER2-positive solid tumors to assess T-cell response.
Interventions
- BIOLOGICAL trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00433407
The ClinicalTrials.gov registry entry for NCT00433407 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which trastuzumab is the first listed.
NCT00433407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00433407 about?
NCT00433407 is a clinical study titled "T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors". RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at blood samples from patients receiving trastuzumab a...
What is the current status of trial NCT00433407?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2005-08.
What interventions are being tested in trial NCT00433407?
The interventions under investigation include: trastuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00433407?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.